Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sun Plunges To Quarterly Loss, Outlook Challenging

Executive Summary

Sun Pharma, India’s biggest drug firm, slid into the red in the first quarter, hit by a hefty legal payout, regulatory woes and a dramatic drop in US sales, and company founder Dilip Shanghvi said while he expected a “gradual improvement” in performance, the outlook remained challenging.

You may also be interested in...



Sun Signs $485m Settlement Deal To Close Out Ranbaxy Antitrust Case

India’s Sun Pharma is set to hand over almost half-a-billion dollars to resolve claims that its Ranbaxy unit schemed to delay the launch of generic versions of three popular prescription drugs. The firm has denied all allegations as part of the deal, which must be signed off by a US district court.

Ilumya Becomes Sun's New Branded Specialty Drug Pillar

FDA approved Ilumya for moderate to severe plaque psoriasis, furthering the competitive dynamics in the crowded psoriasis market, and establishing the biologic as a major pillar of Sun's new branded specialty drug business.

US Pricing Squeeze Clouds Sun Pharma Q2; Site Re-Inspection Critical

Further evidence of the impact of pricing pressure in the US was provided when Sun Pharma reported a sharp fall in profits in Q2 (although it beat the expectations of some analysts). Sun also expects a delay in EU approval for its late stage psoriasis asset, tildrakizumab, but US approval timelines appear unchanged, at least for now.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC099311

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel